GlobeNewswire - Industry News on Health Care Contains the last 20 releases uuid:99a7fd3c-33db-4b85-aa07-ae662e902ec7;id=10001 2021-02-06T01:03:25Z newsdesk@globenewswire.com (NewsDesk) http://www.10gbhost.com/LegacyRss?Length=4 newsdesk@globenewswire.com http://www.10gbhost.com/news-release/2021/02/06/2170951/0/en/Mining-for-Miracles-Launches-2021-Campaign-to-Establish-Cellular-and-Regenerative-Medicine-Centre-CRMC-at-BC-Children-s-Hospital.html Mining for Miracles Launches 2021 Campaign to Establish Cellular and Regenerative Medicine Centre (CRMC) at BC Children’s Hospital 2021-02-06T01:03:25Z 2021-02-06T06:04:56Z The $3.385M initiative will be the first of its kind in Western Canada]]> 2170951 en GlobeNewswire Inc. BC Children's Hospital Foundation Sat, 06 Feb 2021 01:03 GMT M4M_Screenshot_1A - FINAL


]]>
GlobeNewswire Inc.
Health Mining for Miracles Buddy the Miner
http://www.10gbhost.com/news-release/2021/02/05/2170941/0/en/January-12-Update.html January 12 Update 2021-02-05T23:00:00Z 2021-02-06T06:04:56Z WARWICK, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ozop Energy Solutions retracts the press release it issued on January 12, 2021 regarding Ozop Energy Solutions entering into a Master Supply Agreement. Ozop did not have authorization to issue the press release, and the agreement referred to in the release has been terminated.

]]>
2170941 en GlobeNewswire Inc. Ozop Energy Solutions, Inc Fri, 05 Feb 2021 23:00 GMT Press releases Ozop Energy Solutions Master Supply Agreement invents designs develops ultra-high power chargers January 12 Update
http://www.10gbhost.com/news-release/2021/02/05/2170934/0/en/Equillium-Announces-Closing-of-30-Million-Registered-Direct-Offering.html Equillium Announces Closing of $30 Million Registered Direct Offering 2021-02-05T22:36:08Z 2021-02-06T06:04:56Z LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.? ?

]]>
2170934 en GlobeNewswire Inc. Equillium, Inc. Fri, 05 Feb 2021 22:36 GMT Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170927/0/en/Pacific-Biosciences-Grants-Equity-Incentive-Award-to-New-Employee.html Pacific Biosciences Grants Equity Incentive Award to New Employee 2021-02-05T22:00:00Z 2021-02-06T06:04:56Z MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”).

]]>
2170927 en GlobeNewswire Inc. Pacific Biosciences of California, Inc. Fri, 05 Feb 2021 22:00 GMT Product / Services Announcement Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170929/0/en/Assembly-Biosciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2021-02-05T22:00:00Z 2021-02-06T06:04:56Z SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment.

]]>
2170929 en GlobeNewswire Inc. Assembly Biosciences, Inc. Fri, 05 Feb 2021 22:00 GMT Company Announcement
http://www.10gbhost.com/news-release/2021/02/05/2170925/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 2021-02-05T21:30:00Z 2021-02-06T06:04:56Z PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

]]>
2170925 en GlobeNewswire Inc. BridgeBio Pharma, Inc. Fri, 05 Feb 2021 21:30 GMT Changes in company's own shares
http://www.10gbhost.com/news-release/2021/02/05/2170910/0/en/Prothena-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 2021-02-05T21:05:00Z 2021-02-06T06:04:56Z DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and?neurodegenerative diseases, today announced that in connection with hiring three new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 75,000 ordinary shares of the Company. The options have an exercise price per share equal to $11.00, which was the closing trading price on February 1, 2021, the date of the grants. The inducement awards will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the date of grants and 1/48th of the underlying shares vesting monthly thereafter over 36 months. The options were granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

]]>
2170910 en GlobeNewswire Inc. Prothena Corporation plc Fri, 05 Feb 2021 21:05 GMT Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170911/0/en/SeaSpine-Reports-Granting-of-Inducement-Awards.html SeaSpine Reports Granting of Inducement Awards 2021-02-05T21:05:00Z 2021-02-06T06:04:56Z CARLSBAD, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has issued inducement awards to nine non-executive employees.

]]>
2170911 en GlobeNewswire Inc. SeaSpine Holdings Corporation Fri, 05 Feb 2021 21:05 GMT Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170913/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2021-02-05T21:05:00Z 2021-02-06T06:04:56Z WALTHAM, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,?Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to fourteen new employees with grant date of February 1, 2021, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2021 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

]]>
2170913 en GlobeNewswire Inc. Apellis Pharmaceuticals, Inc. Fri, 05 Feb 2021 21:05 GMT Changes in company's own shares
http://www.10gbhost.com/news-release/2021/02/05/2170908/0/en/argenx-announces-closing-of-global-offering.html argenx announces closing of global offering 2021-02-05T21:01:00Z 2021-02-06T06:04:56Z Regulated information

]]>
2170908 en GlobeNewswire Inc. argenx SE Fri, 05 Feb 2021 21:01 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170889/0/zh-hans/AIM-ImmunoTech%E5%AE%8C%E6%88%90%E5%B9%B6%E7%BB%93%E6%9D%9F%E4%BA%86ATM%E5%B7%A5%E5%85%B7-%E5%BD%93%E5%89%8D%E8%B5%84%E9%87%91%E6%9C%89%E6%9C%9B%E6%BB%A1%E8%B6%B3%E5%BD%93%E5%89%8D%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C%E7%9A%84%E9%9C%80%E6%B1%82.html AIM ImmunoTech完成并結束了ATM工具;當前資金有望滿足當前臨床試驗的需求 2021-02-05T19:21:02Z 2021-02-06T06:04:56Z 佛羅里達州奧卡拉, Feb. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(紐約證券交易所股票代碼:AIM)今天宣布已經完成了其市價(ATM)工具,并結束了ATM的股票發行協議(EDA)。管理層相信,根據公司當前的財務狀況,公司有足夠的資金來滿足其預期的運營現金需求,并在未來大約二十四個月內都為當前的臨床試驗提供資金。

]]>
2170889 zh-Hans GlobeNewswire Inc. AIM ImmunoTech Inc. Fri, 05 Feb 2021 19:21 GMT Financing Agreements Health Product / Services Announcement
http://www.10gbhost.com/news-release/2021/02/05/2170889/0/ja/AIM-ImmunoTech-%E9%80%B2%E8%A1%8C%E4%B8%AD%E3%81%AE%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A8%93%E3%83%8B%E3%83%BC%E3%82%BA%E3%81%AB%E5%AF%BE%E5%BF%9C%E3%81%99%E3%82%8B%E8%B3%87%E9%87%91%E3%82%92%E7%A2%BA%E4%BF%9D%E6%B8%88%E3%81%BF%E3%81%A8%E3%81%97%E3%81%A6-ATM%E3%83%95%E3%82%A1%E3%82%B7%E3%83%AA%E3%83%86%E3%82%A3%E3%82%92%E5%AE%8C%E4%BA%86-%E3%82%AF%E3%83%AD%E3%83%BC%E3%82%BA.html AIM ImmunoTech、進行中の臨床試験ニーズに対応する資金を確保済みとして、ATMファシリティを完了、クローズ 2021-02-05T19:21:02Z 2021-02-06T06:04:56Z フロリダ州オカラ発, Feb. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) は本日、アットザマーケット (ATM) ファシリティを完了し、ATMエクイティ?ディストリビューション契約 (EDA) をクローズしたことを発表した。経営陣は、同社の現在の財務狀況は予想される運転資金ニーズを満たしており、今後約24か月間、進行中の臨床試験に資金を提供するのに十分な資金が確保されていると確信している。

]]>
2170889 ja GlobeNewswire Inc. AIM ImmunoTech Inc. Fri, 05 Feb 2021 19:21 GMT Financing Agreements Health Product / Services Announcement
http://www.10gbhost.com/news-release/2021/02/05/2170888/0/en/Amendment-Trading-by-management-and-close-relations-of-management.html Amendment: Trading by management and close relations of management 2021-02-05T19:17:00Z 2021-02-06T06:04:56Z Please read the full announcement in?PDF

]]>
2170888 en GlobeNewswire Inc. Novozymes A/S Fri, 05 Feb 2021 19:17 GMT Insider's Buy/Sell European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170885/0/en/TG-Therapeutics-Announces-FDA-Accelerated-Approval-of-UKONIQ-umbralisib.html TG Therapeutics Announces FDA Accelerated Approval of UKONIQ? (umbralisib) 2021-02-05T18:55:00Z 2021-02-06T06:04:56Z UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

]]>
2170885 en GlobeNewswire Inc. TG Therapeutics, Inc. Fri, 05 Feb 2021 18:55 GMT Health
http://www.10gbhost.com/news-release/2021/02/05/2170857/0/en/Professional-Claims-Bureau-Inc-Joins-Meduit-to-Expand-Market-Share-and-Services-as-One-of-the-Nation-s-Largest-Healthcare-Revenue-Cycle-Solutions-Companies.html Professional Claims Bureau, Inc. Joins Meduit to Expand Market Share and Services as One of the Nation’s Largest Healthcare Revenue Cycle Solutions Companies 2021-02-05T17:00:00Z 2021-02-06T06:04:56Z CHARLOTTE, N.C., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Meduit, one of the top five healthcare revenue cycle solutions companies in the country, announced today that Professional Claims Bureau, Inc. (PCB) has joined forces with Meduit. Together, the two companies will leverage their combined broad and complementary revenue cycle management (RCM) capabilities to fuel strategic growth in the healthcare sector.

]]>
2170857 en GlobeNewswire Inc. Meduit Fri, 05 Feb 2021 17:00 GMT Partnerships Meduit Revenue Cycle Management Revenue Cycle Solutions
http://www.10gbhost.com/news-release/2021/02/05/2170860/0/en/Valneva-D%C3%A9claration-d-actions-et-de-droits-de-vote-Janvier-2021.html Valneva - Déclaration d’actions et de droits de vote – Janvier 2021 2021-02-05T17:00:00Z 2021-02-06T06:04:56Z VALNEVA

]]>
2170860 en GlobeNewswire Inc. VALNEVA Fri, 05 Feb 2021 17:00 GMT Law & Legal Issues European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170862/0/en/EssilorLuxottica-Disclosure-of-Share-Capital-and-Voting-Rights-Outstanding-as-of-January-31-2021.html EssilorLuxottica : Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2021 2021-02-05T17:00:00Z 2021-02-06T06:04:56Z Disclosure of Share Capital and Voting Rights Outstanding
as of January 31, 2021

]]>
2170862 en GlobeNewswire Inc. EssilorLuxottica Fri, 05 Feb 2021 17:00 GMT Changes in share capital and votes European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170862/0/fr/EssilorLuxottica-Nombre-total-de-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-janvier-2021.html EssilorLuxottica : Nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2021 2021-02-05T17:00:00Z 2021-02-06T06:04:56Z Nombre total de droits de vote et d’actions
composant le capital social au 31 janvier 2021

]]>
2170862 fr GlobeNewswire Inc. EssilorLuxottica Fri, 05 Feb 2021 17:00 GMT Changes in share capital and votes European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170844/0/en/Bright-Minds-Biosciences-Announces-Listing-on-Canadian-Stock-Exchange.html Bright Minds Biosciences Announces Listing on Canadian Stock Exchange 2021-02-05T16:30:00Z 2021-02-06T06:04:56Z VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced that the Company’s common shares (the “Shares”) are expected to commence trading on the Canadian Securities Exchange (the “CSE”) on Monday, February 8, 2021, under the ticker symbol “DRUG.”

]]>
2170844 en GlobeNewswire Inc. Bright Minds Biosciences Fri, 05 Feb 2021 16:30 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170845/0/en/Corizon-Health-Names-Dr-Leonora-Muhammad-AVP-of-Patient-Care-Services.html Corizon Health Names Dr. Leonora Muhammad AVP of Patient Care Services 2021-02-05T16:30:00Z 2021-02-06T06:04:56Z BRENTWOOD, Tenn., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Corizon Health announced today that the company has promoted Leonora Muhammad, DNP, BSN, APRN, AGPCNP-BC, CCHP, to Associate Vice President of Patient Care Services.

]]>
2170845 en GlobeNewswire Inc. Corizon Health, Inc. Fri, 05 Feb 2021 16:30 GMT Company Announcement Health Correctional healthcare Corrections City of St. Louis St. Louis City St. Louis jails
亚洲精品私拍国产在线播放_亚洲综合区图片小说区_亚洲日本欧美日韩高观看